PE16399A1 - Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores - Google Patents
Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptoresInfo
- Publication number
- PE16399A1 PE16399A1 PE1997001070A PE00107097A PE16399A1 PE 16399 A1 PE16399 A1 PE 16399A1 PE 1997001070 A PE1997001070 A PE 1997001070A PE 00107097 A PE00107097 A PE 00107097A PE 16399 A1 PE16399 A1 PE 16399A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- guanidinyl
- alkynyl
- formula
- alpha
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- -1 GUANIDINYL Chemical class 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 abstract 2
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 206010033078 Otitis media Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Quinoline Compounds (AREA)
Abstract
SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES H, ALQUILO o NO EXISTE, CUANDO EL ENLACE (a) ES UN DOBLE ENLACE; "B" ES NR9, CR3=CR8, S, ENTRE OTROS; "D" ES CR2 o SI B ES CR3, ENTONCES "D" PUEDE SER NITROGENO, EN DONDE: R2 ES H, ALQUILO C1-C3, AMINO, ENTRE OTROS; R9 ES H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO; R3, R7 Y R8 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO, ALQUILTIO C1-C3, ALCOXI C1-C3, ENTRE OTROS; R4, R5 Y R6 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ENTRE OTROS, CON LA CONDICION DE QUE UNO DE R4, R5 Y R6 ES NH-C(=NR10)NHR11 (GUANIDINILO), EN DONDE: R10 Y R11 ES H, METILO Y ETILO; SIENDO UN COMPUESTO (I) PREFERIDO: (4-METILBENCIMIDAZOL-5-IL)GUANIDINA. TAMBIEN SE REFIERE A LA COMPOSICION QUE COMPRENDE UN COMPUESTO DE FORMULA (I) Y UNO O MAS PRINCIPIOS ACTIVOS COMO UN ANTIHISTAMINICO, ANTIINFLAMATORIO, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTA DE ALFA 2 ADRENORECEPTORES, SIENDO UTILES EN EL TRATAMIENTO DE CONGESTION NASAL, OTITIS MEDIA, SINUSITIS, ASMA, DOLOR, MIGRANA, ABUSO DE SUSTANCIA Y ADICCION, TRASTORNO GASTROINTESTINAL, ULCERA, HIPERACIDEZ ESTOMACAL, HIPERTROFIA PROSTATICA BENIGNA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3202396P | 1996-11-25 | 1996-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE16399A1 true PE16399A1 (es) | 1999-03-12 |
Family
ID=21862692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1997001070A PE16399A1 (es) | 1996-11-25 | 1997-11-25 | Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6225331B1 (es) |
| EP (1) | EP0944604B1 (es) |
| JP (1) | JP2001506600A (es) |
| KR (1) | KR20000069131A (es) |
| CN (1) | CN1104422C (es) |
| AR (1) | AR009145A1 (es) |
| AT (1) | ATE286885T1 (es) |
| AU (1) | AU730369B2 (es) |
| BR (1) | BR9713536A (es) |
| CA (1) | CA2272640C (es) |
| CO (1) | CO4910148A1 (es) |
| CZ (1) | CZ184099A3 (es) |
| DE (1) | DE69732244T2 (es) |
| ES (1) | ES2236833T3 (es) |
| HU (1) | HUP0000312A3 (es) |
| ID (1) | ID23857A (es) |
| IL (1) | IL130077A0 (es) |
| NO (1) | NO313912B1 (es) |
| NZ (1) | NZ336010A (es) |
| PE (1) | PE16399A1 (es) |
| RU (1) | RU2194700C2 (es) |
| SK (1) | SK69799A3 (es) |
| TR (1) | TR199901468T2 (es) |
| WO (1) | WO1998023596A1 (es) |
| ZA (1) | ZA9710578B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU730369B2 (en) | 1996-11-25 | 2001-03-08 | Board Of Regents Of The University Of Nebraska, The | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| US6291514B1 (en) * | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
| DZ3415A1 (fr) * | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| BR0113747A (pt) * | 2000-09-08 | 2003-06-24 | Warner Lambert Co | Prevenção de sinusite aguda e ataque sinusal |
| DK1385823T3 (da) * | 2001-04-09 | 2007-03-26 | Novartis Vaccines & Diagnostic | Guanidinoforbindelser som melanocortin-4-receptor- (MC4-R) -agonister |
| US20030195187A1 (en) * | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
| US20050124652A1 (en) * | 2002-02-04 | 2005-06-09 | Rustum Boyce | Guanidino compounds |
| US20030207814A1 (en) * | 2002-02-04 | 2003-11-06 | Chiron Corporation | Novel guanidinyl derivatives |
| JP2005524649A (ja) * | 2002-02-25 | 2005-08-18 | カイロン コーポレーション | Ｍｃ４−ｒアゴニストの鼻腔内投与 |
| EP1551834B1 (en) | 2002-05-23 | 2010-08-25 | Novartis Vaccines and Diagnostics, Inc. | Substituted quinazolinone compounds |
| KR20060018217A (ko) * | 2003-05-23 | 2006-02-28 | 카이론 코포레이션 | Ｍｃ4-ｒ 작용제로서 구아니디노-치환된 퀴나졸리논 화합물 |
| RU2254855C2 (ru) * | 2003-09-10 | 2005-06-27 | Открытое акционерное общество "Акционерное курганское общество медицинских препаратов и изделий "Синтез" | Противовирусное средство и способ его получения |
| WO2005051391A1 (en) * | 2003-11-19 | 2005-06-09 | Chiron Corporation | Quinazolinone compounds with reduced bioaccumulation |
| CA2605073C (en) * | 2005-04-13 | 2017-12-12 | Neuraxon, Inc. | Substituted indole compounds having nos inhibitory activity |
| US20070225217A1 (en) | 2005-11-09 | 2007-09-27 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
| US8173813B2 (en) * | 2007-03-23 | 2012-05-08 | Neuraxon, Inc. | Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity |
| MX2010005343A (es) * | 2007-11-16 | 2010-08-09 | Neuraxon Inc | Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina. |
| US20100196286A1 (en) * | 2008-12-01 | 2010-08-05 | Armer Thomas A | Inhalation delivery methods and devices |
| WO2010074753A1 (en) | 2008-12-23 | 2010-07-01 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
| GB0919889D0 (en) * | 2009-11-13 | 2009-12-30 | Biocopea Ltd | Drug composition and its use in therapy |
| JP5959537B2 (ja) * | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリジニル−ピリミジン及び医薬としてのその使用 |
| CN112047947A (zh) * | 2020-10-13 | 2020-12-08 | 石药集团新诺威制药股份有限公司 | 一种茶碱的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU148414A1 (ru) * | 1961-07-03 | 1961-11-30 | Е.Н. Зильберман | Способ получени имидазолов и оксазолов |
| US3908013A (en) | 1970-09-17 | 1975-09-23 | Armour Pharma | Pharmaceutical aromatic guanidine compositions and methods of using same |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US3947455A (en) | 1974-04-15 | 1976-03-30 | Armour Pharmaceutical Company | 5'-(8'-Hydroxyquinolyl)guanidine compounds |
| US4000279A (en) | 1974-10-29 | 1976-12-28 | Armour Pharmaceutical Company | Pharmaceutical preparations containing 5'-(8'-hydroxyquinolyl)guanidine compounds and methods of using same |
| KR860002082A (ko) * | 1984-08-29 | 1986-03-26 | 프랑시스 글로리 | 자기 변환기 헤드 구조물 |
| NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
| US5091528A (en) | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
| AU701233B2 (en) * | 1993-12-17 | 1999-01-21 | Procter & Gamble Company, The | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| AU730369B2 (en) | 1996-11-25 | 2001-03-08 | Board Of Regents Of The University Of Nebraska, The | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| JP2001507349A (ja) * | 1996-12-23 | 2001-06-05 | セルテック セラピューティックス リミテッド | 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用 |
-
1997
- 1997-11-21 AU AU54381/98A patent/AU730369B2/en not_active Ceased
- 1997-11-21 ID IDW990410A patent/ID23857A/id unknown
- 1997-11-21 KR KR1019997004619A patent/KR20000069131A/ko not_active Ceased
- 1997-11-21 ES ES97948290T patent/ES2236833T3/es not_active Expired - Lifetime
- 1997-11-21 SK SK697-99A patent/SK69799A3/sk unknown
- 1997-11-21 CA CA002272640A patent/CA2272640C/en not_active Expired - Fee Related
- 1997-11-21 US US09/308,788 patent/US6225331B1/en not_active Expired - Lifetime
- 1997-11-21 DE DE69732244T patent/DE69732244T2/de not_active Expired - Lifetime
- 1997-11-21 WO PCT/US1997/020802 patent/WO1998023596A1/en not_active Ceased
- 1997-11-21 CN CN97181078A patent/CN1104422C/zh not_active Expired - Fee Related
- 1997-11-21 JP JP52469498A patent/JP2001506600A/ja active Pending
- 1997-11-21 NZ NZ336010A patent/NZ336010A/en unknown
- 1997-11-21 AT AT97948290T patent/ATE286885T1/de not_active IP Right Cessation
- 1997-11-21 IL IL13007797A patent/IL130077A0/xx unknown
- 1997-11-21 CZ CZ991840A patent/CZ184099A3/cs unknown
- 1997-11-21 BR BR9713536-4A patent/BR9713536A/pt not_active IP Right Cessation
- 1997-11-21 HU HU0000312A patent/HUP0000312A3/hu unknown
- 1997-11-21 EP EP97948290A patent/EP0944604B1/en not_active Expired - Lifetime
- 1997-11-21 TR TR1999/01468T patent/TR199901468T2/xx unknown
- 1997-11-21 RU RU99113446/04A patent/RU2194700C2/ru not_active IP Right Cessation
- 1997-11-24 CO CO97068606A patent/CO4910148A1/es unknown
- 1997-11-25 ZA ZA9710578A patent/ZA9710578B/xx unknown
- 1997-11-25 AR ARP970105530A patent/AR009145A1/es unknown
- 1997-11-25 PE PE1997001070A patent/PE16399A1/es not_active Application Discontinuation
-
1999
- 1999-05-25 NO NO19992498A patent/NO313912B1/no unknown
-
2000
- 2000-12-01 US US09/727,900 patent/US6391878B2/en not_active Expired - Lifetime
-
2002
- 2002-02-08 US US10/071,284 patent/US20020128481A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE16399A1 (es) | Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores | |
| PE16299A1 (es) | Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores | |
| PE106499A1 (es) | Antagonistas del receptor ccr-3 | |
| ATE416157T1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| PE20091093A1 (es) | Compuesto heterociclico que contiene nitrogeno y su uso | |
| PE20081557A1 (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| SE8500368D0 (sv) | Heterocykliska foreningar | |
| TR200103335T2 (tr) | Proteaz inhibitörleri olarak amin türevleri | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| DE3850203D1 (de) | Benzimidazolin-2-oxo-1-carboxylsäure-Derivate, verwendbar als Antagonisten von 5-HT-Rezeptoren. | |
| AR247213A1 (es) | Preparacion de acido 7-¡(1-carboxi-3-fenilpropil)amino¿-3,4,6,7,8,12b-octahidro-6-oxopirido ¡2,1-a¿ o hexahidro-6-oxo-1h(1,4-tiazino¡3,4-a¿¡2¿-benzazepin-4-carboxilico, agentes hipertensivos. | |
| ES2172580T3 (es) | 1,3-oxatiolanos sustituidos con propiedades antiviricas. | |
| PE20050460A1 (es) | COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO) | |
| DE59914814D1 (de) | Heterozyklische substituierte amide, deren herstellung und anwendung | |
| PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| BR0000654A (pt) | Preparação de composição de borracha vulcanizada com peróxido e artigos tendo ela pelo menos como um dos seus componentes | |
| PE20001084A1 (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
| PE83999A1 (es) | Azetidinas | |
| CO5271666A1 (es) | Derivados de pirimidina | |
| PE29798A1 (es) | Acetidinas | |
| PE16599A1 (es) | Compuestos de (2-imidazolinilamino) benzoxazol utiles como agonistas de alfa-2 adrenoreceptores | |
| ES2180932T3 (es) | Derivados de camptotecina y su uso como agentes antitumorales. | |
| IT1271411B (it) | Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare | |
| NO20002655D0 (no) | 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet | |
| CO4770917A1 (es) | Compuestos de dihalopropeno, su uso e intermedios para su produccion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |